Loading...
Market
What will be the total US sales of Leqembi by December 31, 2024?
3
Resolution / Starting Odds
More than $500 million • 25%
$300 million to $500 million • 25%
$100 million to $300 million • 25%
Less than $100 million • 25%
Sales data from Eisai and Biogen's quarterly financial reports
Story
EU Regulator Rejects Leqembi for Early Alzheimer's Disease; Biogen Stock Falls 6.7%
Jul 26, 2024, 11:23 AM
The European Union's drugs regulator has rejected Eisai and Biogen's Alzheimer's drug, Leqembi, for early Alzheimer's disease, citing concerns over its safety profile. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion, stating that the observed effect of Leqembi on delaying cognitive decline does not outweigh the risk of serious adverse events. The decision also noted the drug's slight advantage over placebo on a clinical dementia rating scale. This contrasts with the U.S. regulators, who have granted full approval for the drug. The rejection is a significant setback for Eisai and Biogen, who were seeking to expand sales in the European market. Following the announcement, Biogen's stock fell by 6.7% in pre-market trading.
View original story
Similar markets
High uptake (over 10,000 patients) • 25%
Moderate uptake (5,000-10,000 patients) • 25%
Low uptake (1,000-5,000 patients) • 25%
Very low uptake (under 1,000 patients) • 25%
Below USD 100 million • 25%
USD 100 million to USD 200 million • 25%
USD 200 million to USD 300 million • 25%
Above USD 300 million • 25%
Less than $100 million • 25%
$100 million - $299 million • 25%
$300 million - $499 million • 25%
$500 million or more • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$201 million to $300 million • 25%
More than $300 million • 25%
Yes, by Eisai/Biogen • 25%
Yes, by regulatory mandate • 25%
No, no price reduction • 25%
Other • 25%
